Thomas Edlund new Chairman of Pharmalink

The Swedish specialty pharmaceutical company Pharmalink announced the appointment of Thomas Eklund as Chairman of the board.

Thomas Eklund joined the board on August 15, 2017.

Bengt Julander, Founder and outgoing Chairman of Pharmalink, said: "We are very happy to have Thomas on board as we prepare for taking our lead candidate drug Nefecon through a clinical Phase 3 study for patients with primary IgA nephropathy.

"Thomas’s broad knowledge and long experience from both the healthcare industry and the financial sector will be a welcome addition to the team."

Thomas has extensive experience from the pharmaceutical industry, medtech industry and the financial sector where he has held different leading positions, including CEO and Head of Europe at Investor Growth Capital.

Other previous positions include Investment Director at Alfred Berg ABN AMRO Capital Investment and VP at Handelsbanken Markets. He is currently Chairman of the board of Moberg Pharma and Itrim, and board member of Boule Diagnostics, Biotage, Neoventa Medical, Memira and Rodebjer Form.

You may also like

Regulatory

EMA issues positive opinion on Calliditas' orphan drug

Calliditas' application for orphan drug designation in the European Union (EU) for setanaxib in Alport syndrome has received a positive opinion from European Medicines Agency
Ingredients

Full details from Calliditas Therapeutics’ Phase 3 study released

Calliditas Therapeutics has announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon delayed release capsules in adults with Primary IgA nephropathy
Regulatory

Calliditas receives fast track FDA designation for PBC candidate

The FDA program facilitates the expedited development and review of new drugs intended to treat serious or life-threatening conditions
Manufacturing

CDMO Adragos Pharma acquires aseptic fill-finish manufacturing expert, Baccinex

Baccinex has significant knowledge in sterile fill-finish processes for both lyophilised and liquid vials
Research & Development

Roche acquires clinical-stage biopharmaceutical company Poseida Therapeutics

Through the merger, Roche will acquire Poseida's allogeneic CAR-T cell therapy portfolio, including pre-clinical and clinical-stage iterations for a range of conditions
Regulatory

Merck's Welireg approved for cancers associated with von Hippel-Lindau disease in China

The once-daily drug is the first HIF-2α to be approved in China, exhibiting a 49% objective response rate (ORR)
Manufacturing

Vetter strengthens senior management team for growth

Three new managing directors to support global sustainable development
Subscribe now